Ecdysterone vs Sermorelin
Moderate Research vs Well Studied
monitor Mechanism-based · 47% Both Ecdysterone and Sermorelin act on estrogen receptors. Receptor competition may reduce effectiveness of one or both. Using multiple SERMs simultaneously is generally not recommended — choose one.
Molecular Data
Ecdysterone Sermorelin
Weight 480.64 Da 3,358 Da
Half-life ~4-9 hours 10-12 minutes
Chain — 29 amino acids
Type Ecdysteroid (C27H44O7) GHRH analog
Key Benefits
Ecdysterone
01 Activation of muscle protein synthesis through ERbeta/PI3K/Akt/mTOR signaling without androgen receptor binding
02 Statistically significant increases in lean muscle mass demonstrated in a controlled human trial in trained subjects
03 No hormonal suppression -- does not affect testosterone, LH, or FSH levels, eliminating the need for post-cycle therapy
04 No androgenic side effects (no hair loss, acne, prostate issues, or virilization in women)
05 No hepatotoxicity, unlike oral anabolic steroids that undergo 17-alpha alkylation
06 Naturally occurring in common foods (spinach, quinoa), with a long history of safe dietary exposure
07 Compatible with other performance compounds due to its non-hormonal mechanism
08 Available as a dietary supplement without prescription in most jurisdictions
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Ecdysterone
500-1000 mg/day (oral) or 50-100 mg/day (injectable) / 1-2x daily
Enhanced Anabolic Effect / Higher Bioavailability 50-100 mg/day Once daily
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Ecdysterone
Mild gastrointestinal discomfort (nausea, bloating, or stomach upset) with oral doses, particularly at higher dosages taken without food
Injection site pain, redness, or mild swelling with injectable administration
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Known allergy to ecdysteroids or spinach-derived compounds
Pregnancy and breastfeeding (insufficient safety data)
Individuals with estrogen-sensitive conditions should consult a physician, though ERbeta activation is generally considered protective rather than proliferative
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Ecdysterone Sermorelin
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2020 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.